Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03899792 · ClinicalTrials.gov registry record · Phase 1
A Study of Oral LOXO-292 (Selpercatinib) in Pediatric Participants With Advanced Solid or Primary Central Nervous System (CNS) Tumors
A Phase 1 study of Soft Tissue Sarcoma and Papillary Thyroid Cancer, sponsored by Eli Lilly and Company.
- Active
- Registry status
- Phase 1
- Development phase
- 36
- Enrollment target
- 20
- Study locations
NCT03899792: Active Phase 1 study of Soft Tissue Sarcoma and Papillary Thyroid Cancer, sponsored by Eli Lilly and Company.
NCT03899792 is a Phase 1 study of Soft Tissue Sarcoma and Papillary Thyroid Cancer that is active but no longer recruiting, run by Eli Lilly and Company. The registered enrollment target is 36 participants, below the 78-participant average among 55 other Soft Tissue Sarcoma trials with a reported enrollment target (54% lower). The trial reports 20 study locations across 18 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03899792, a Phase 1 study of Soft Tissue Sarcoma and Papillary Thyroid Cancer, is active but no longer recruiting, sponsored by Eli Lilly and Company.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 36 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is an open-label, multi-center Phase 1/2 study of oral LOXO-292 in pediatric participants with an activating rearranged during transfection (RET) alteration and an advanced solid or primary CNS tumor.
Primary Outcome
A DLT was any of the adverse events that starts on or after the first administration of study drug listed below, as defined by the National Cancer Institute's Common Terminology Criteria for Adverse Events (NCI CTCAE) v5.0. * Any Grade(G) ≥3 nonhematologic toxicity except G3 fatigue, nausea, tendon reflex decrease, weight gain attributable to normal growth and development. * G3 vomiting/diarrhea was DLT only if it persists \>48 h despite standard of care treatment. * G4 vomiting/diarrhea was DL
Conditions Studied
Interventions
- DRUG Selpercatinib
Study Locations (20)
Texas
- University of Texas Southwestern Medical Center at Dallas - Dallas
- Texas Childrens Hospital - Houston
Other
- Rigshospitalet - Copenhagen
- Gustave Roussy - Villejuif
California
- Childrens Hospital of Los Angeles - Los Angeles
Colorado
- The Children's Hospital for Cancer and Blood Disorders - Aurora
Florida
- Nemours Children's Health - Orlando
Massachusetts
- Dana-Farber Cancer Institute - Boston
Minnesota
- University of Minnesota Hospital - Minneapolis
New York
- Memorial Sloan Kettering Cancer Center - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 2019-06-13 |
| Est. Completion | 2029-05 |
| Phase | Phase 1 |
What the registry record for NCT03899792 still lists
NCT03899792 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 36 participants, a relatively small participant target, below the 78-participant average among 55 other Soft Tissue Sarcoma trials with a reported enrollment target (54% lower).
The record links to 5 conditions, with Soft Tissue Sarcoma appearing as the primary indexed condition, and to 1 intervention - of which Selpercatinib is the first listed.
NCT03899792 names 20 study sites across 18 states, led by Texas, Other, California.
Frequently Asked Questions
What is clinical trial NCT03899792 about?
NCT03899792 is a clinical study titled "A Study of Oral LOXO-292 (Selpercatinib) in Pediatric Participants With Advanced Solid or Primary Central Nervous System (CNS) Tumors". This is an open-label, multi-center Phase 1/2 study of oral LOXO-292 in pediatric participants with an activating rearranged during transfection (RET) alteration and an advanced solid or primary CNS tumor.
What is the current status of trial NCT03899792?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 36 participants. The study started on 2019-06-13. Estimated completion is 2029-05.
What conditions does trial NCT03899792 study?
This clinical trial studies the following conditions: Soft Tissue Sarcoma, Papillary Thyroid Cancer, Medullary Thyroid Cancer, Infantile Fibrosarcoma, Infantile Myofibromatosis.
What interventions are being tested in trial NCT03899792?
The interventions under investigation include: Selpercatinib (DRUG).
Who is sponsoring clinical trial NCT03899792?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03899792 being conducted?
This trial has 20 study locations across California, Colorado, Florida, Massachusetts, Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Soft Tissue Sarcoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03899792's enrollment target sits among peer trials
36 33rd of 55 higher than 23 of 55 other Soft Tissue Sarcoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Soft Tissue Sarcoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Study of Autologous Tumor-Infiltrating Lymphocytes in Pediatric, Adolescent, and Young Adult Participants
RECRUITING · Phase 1
-
A Study Evaluating the Safety, Pharmacokinetics and Early Efficacy of AVA6000 in Solid Tumours
RECRUITING · Phase 1
-
HER2 Chimeric Antigen Receptor (CAR) T Cells in Combination With Checkpoint Blockade in Patients With Advanced Sarcoma
RECRUITING · Phase 1
-
A First-In-Human Phase 1 Trial of T-Cell Membrane-Anchored Tumor Targeted Il12 (Attil12)- T-Cell Therapy in Subjects With Advanced/Metastatic Soft Tissue and Bone Sarcoma
RECRUITING · Phase 1
-
Retifanlimab (Anti-PD-1 Antibody) With Gemcitabine and Docetaxel in Patients With Advanced Soft Tissue Sarcoma
RECRUITING · Phase 1
-
Novel RNA-lipid Particle (RNA-LP) Vaccine for Anti-PD-1 Antibody Therapy Sensitization
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00929006 · 36 participants · Early Phase 1
Acute Progesterone Suppression of Wake vs. Sleep Luteinizing Hormone Pulse Frequency in Pubertal Girls With and Without Hyperandrogenism
- NCT01891318 · 36 participants · Phase 1
Neoadjuvant Radiosurgery for Resectable Brain Metastases: Phase I/II Study
- NCT02291848 · 36 participants · Phase 1
Tumor-Associated Antigen-Specific Cytotoxic T-Lymphocytes for Multiple Myeloma
- NCT02366819 · 36 participants · Phase 4
Genetic Analysis-Guided Irinotecan Hydrochloride Dosing of mFOLFIRINOX in Treating Patients With Locally Advanced Gastroesophageal or Stomach Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI